By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Dynamic Business Location.

APEIRON Biologics given green light for market approval

Hans Loibner, Apeiron CEO © Apeiron

The development of dinutuximab beta originally began at the Clinical Cancer Research Institute of St. Anna Children’s Hospital in Vienna and was extended to encompass numerous clinical studies throughout Europe and abroad.

In 2011, Apeiron acquired commercial rights to the project, and then led efforts to win market approval in cooperation with academic groups. More than 1,000 patients have been treated up until now. In September 2016, Apeiron EUSA Pharma acquired an exclusive license to the global commercial rights to dinutuximab beta.

The CHMP recommendation issued on March 24, 2017 will be presented to the European Commission by the EMA. The European Commission will issue a formal decision on the approval of dinutuximab beta within the next two months.

Neuroblastoma is the third most frequent malignant tumor afflicting children. The tumors arise from cells of so-called autonomic nervous system. The apparent cause is that cells do not sufficiently mature in their development phase and then begin to reproduce themselves later in an unrestrained manner. About one out of every 5,000 children suffers from this illness. One third of the tumors already occur in children’s first year.

 

About APEIRON Biologics AG

Apeiron is a private biotech company in Vienna, Austria developing innovative projects in the field of immune-oncology..

For more information: www.apeiron-biologics.com

 

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • Meet us @ ARIT — Austrian Research & Innovation Talk

    18.09.2021/ 9.00am - 4.00pm EDT, Convene 600 14th St NW Washington, DC 20005 or via livestream

  • TECHNOLOGY CAMPUS TIROL

    22.09.2021/ 11.30 Uhr, LA Villa Starnberger See/ Ferdinand-von-Miller-Straße 39-41, 82343 Niederpöcking

Austria Map

Find the perfect location for your company

The openness towards innovations, that one can find everywhere within Austria was our basis to bring FAIRTIQ to Austria first, after Switzerland and Liechtenstein. FAIRTIQ is looking forward to accompany our existing and also our new partners in Austria on all their upcoming and successful journeys.

FAIRTIQ

Logo: FAIRTIQ
More testimonials

news from the business location Austria

Smurfit Kappa launches district heat project

Just under a year after the new energy systems went into operation, the next major sustainability project relating to the facility in Upper Austria is already in the starting blocks for the Irish group Smurfit Kappa Nettingsdorf.

Corona Tracking: New Encryption Technology Ensures Data Protection

The “Corona Heatmap” developed by the Know-Center and the Graz University of Technology shows where people who tested positive for the coronavirus were before the diagnosis i.e., the precise location where they got infected. In this way, conclusions can be drawn about coronavirus hotspots. An innovative process the interface between cryptography and data analysis ensures the necessary data protection.

More news All blog posts